摘要:
A gene coding for Protein H, which is capable of binding specifically to human IgG of all subclasses, was isolated from Streptococcus sp. APl and expressed in host cells, E. coli to produce the Protein H.
摘要:
A gene coding for Protein H, which is capable of binding specifically to human IgG of all subclasses, was isolated from Streptococcus sp. AP1 and expressed in host cells, E. coli to produce the Protein H.
摘要:
A nuclear delivery construct comprises (i) protein H or a fragment or derivative thereof that is capable of being targeted to the nucleus of a eukaryotic cell; and associated therewith (ii) one or more other components whose targeting to the nucleus of the eukaryotic cell is desired.
摘要:
A process is disclosed for recovering a cell wall protein, particularly a Fc-receptor, from streptococcal bacteria. In the process, streptococcal bacteria are treated with at least one proteolytic enzyme to solubilize the cell wall protein. A process is also disclosed for recovering Fc-receptor type III (protein G) having selective IgG-binding capability (i.e., no albumin-binding capability) from streptococcal bacteria by pretreating these bacteria with enzymes prior to said enzymatic solubilization.
摘要:
A polypeptide isolated from S. pyogenes is described, having IgG cysteine protease activity. The protease is designated IdeS, Immunoglobulin G-degrading enzyme of S. pyogenes. A polypeptide comprises SEQ ID NO: 1 and variants and fragments thereof having IgG cysteine protease activity or the ability to generate an immune response against S. pyogenes in an individual. Polynucleotides encoding these polypeptides and the polypeptides may be used in generating an immune response in an individual. IdeS protease inhibitors may be used in the treatment of S. pyogenes infection.
摘要翻译:描述了从化脓性链球菌分离的多肽,其具有IgG半胱氨酸蛋白酶活性。 蛋白酶被命名为化脓性链球菌的IdeS,免疫球蛋白G降解酶。 多肽包含SEQ ID NO:1及其具有IgG半胱氨酸蛋白酶活性的变体和片段或在个体中产生抗化脓性链球菌的免疫应答的能力。 编码这些多肽和多肽的多核苷酸可用于在个体中产生免疫应答。 IdeS蛋白酶抑制剂可用于治疗化脓性链球菌感染。
摘要:
The invention relates to sequences of protein L which bind to light chains of immunoglobulins. The invention also relates to hybrid proteins thereof which are able to bind to both light and heavy chains of immunoglobulin G, in particular protein LG. The invention also relates to DNA-sequences which code for the proteins, vectors which include such DNA-sequences, host cells which have been transformed with the vectors, methods for producing the proteins, reagent appliances for separation and identification of immunoglobulins, compositions and pharmaceutical compositions and pharmaceutical compositions which contain the proteins.
摘要:
The invention provides use of an EndoS polypeptide, or a polynucleotide encoding an EndoS polypeptide, in the manufacture of a medicament for the treatment or prevention of a disease or condition mediated by IgG antibodies.
摘要:
A polypeptide isolated from S. pyogenes is described, having IgG cysteine protease activity. The protease is designated IdeS, Immunoglobulin G-degrading enzyme of S. pyogenes. A polypeptide comprises SEQ ID NO: 1 and variants and fragments thereof having IgG cysteine protease activity or the ability to generate an immune response against S. pyogenes in an individual. Polynucleotides encoding these polypeptides and the polypeptides may be used in generating an immune response in an individual. IdeS protease inhibitors may be used in the treatment of S. pyogenes infection.
摘要翻译:描述了从化脓性链球菌分离的多肽,其具有IgG半胱氨酸蛋白酶活性。 蛋白酶被命名为化脓性链球菌的IdeS,免疫球蛋白G降解酶。 多肽包含SEQ ID NO:1及其具有IgG半胱氨酸蛋白酶活性的变体和片段或在个体中产生抗化脓性链球菌的免疫应答的能力。 编码这些多肽和多肽的多核苷酸可用于在个体中产生免疫应答。 IdeS蛋白酶抑制剂可用于治疗化脓性链球菌感染。
摘要:
A hybrid DNA molecule is disclosed by this invention capable of cellular expression comprising the DNA sequence for protein G. Said DNA sequence has substantially the same IgC binding properties as naturally occurring protein G. The molecule may be comprised of DNA sequences coding for fragments of protein G. Moreover, said DNA sequence may code for both fragments of protein G and protein G. The DNA sequence can be isolated from streptococcal DNA.
摘要:
A method of identifying an agent that enhances the anti-microbial activity of cationic anti-microbial peptides by blocking the inhibitory effects of the proteinase/glycosaminoglycan pathway, which method comprises: (i) providing, as a first component, a cationic anti-microbial peptide; (ii) providing, as a second component, bacteria; (iii) providing, as a third component, part of all of the components of a proteinase/glycosaminoglycan pathway such that the third component reduces the antimicrobial effect of the first component, for example, a glycosaminoglycan or bacteria or bacteria and a proteoglycan or a bacterial proteinase or a bacterial proteinase and a proteoglycan; (iv) contacting the first, second and third components with a test agent under conditions that would permit the killing of the bacteria by the antimicrobial agent in the absence of the third component, and that would permit the inhibition of the anti-microbial activity of the first component by the third component in the absence of the test agent; (v) monitoring the survival of the bacterial culture thereby determining whether the test agent is capable of enhancing anti-microbial activity wherein a test agent capable of enhancing anti-microbial activity promotes killing of the bacterial culture. Agents identified by such a method are useful in the therapy of acute and chronic infections, particularly in the treatment of ulcers and in the promotion of wound healing.